ENTITY
Zhaoke Ophthalmology

Zhaoke Ophthalmology (6622 HK)

35
Analysis
Health Care • China
Zhaoke Ophthalmology is an ophthalmic pharmaceutical company focused on the research, development, manufacturing, and commercialization of therapies for unmet medical needs in eye diseases. Its comprehensive drug portfolio addresses conditions such as dry eye disease, myopia, presbyopia, wet age-related macular degeneration, diabetic macular edema, and glaucoma. The company was founded in 2017 and is headquartered in Guangzhou, China.
more
•06 Apr 2021 11:03

Zhaoke Ophthalmic (å…†ē§‘ēœ¼ē§‘) Pre-IPO: Thoughts on Valuation

In this note, we provide a forecast on Zhaoke Ophthalmic's two core products CsA ophthalmic gel and the ZKY001 and an SOTP based valuation for the...

Logo
657 Views
Share
bullish•Linklogis
•05 Apr 2021 12:18

ECM Weekly (5th April 2021) - Nayuki, Peter Warren, Linklogis, Zhaoke Ophthalmic, Macrotech Dev

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
•30 Mar 2021 12:26

Zhaoke Ophthalmic (å…†ē§‘ēœ¼ē§‘): Could Be Over-Valued for Pre-IPO Round

The company has an OK management team but strong backing of institutional investors. We think the pre-IPO valuation could be too high.

Logo
607 Views
Share
•09 Mar 2021 09:28

Pre-IPO Zhaoke Ophthalmology Pharmaceutical - It Remains to Be Seen How to Find Its Way Out

The article analyzed Zhaoke Ophthalmology in terms of pipeline, competitive landscape, financial position and also included concerns for the future...

Logo
786 Views
Share
•18 Feb 2021 01:03

Zhaoke Ophthalmology: Bringing Focus to China

Zhaoke Ophthalmology is a pre-revenue pharmaceutical company specializing in ophthalmic drugs for China that has filed to list on the HKEX. Lee's...

Share
x